Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ADMA NASDAQ:PHAT NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.81+0.4%$23.31$13.40▼$26.65$3.67B0.752.17 million shs412,372 shsADMAADMA Biologics$16.02+5.1%$15.85$13.50▼$25.67$3.80B0.473.16 million shs1.47 million shsPHATPhathom Pharmaceuticals$13.28-2.4%$11.97$2.21▼$19.50$945.28M0.431.64 million shs180,518 shsTLXTelix Pharmaceuticals$10.79-0.8%$10.29$8.93▼$30.36$3.66BN/A79,832 shs26,136 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ADMAADMA Biologics+0.59%+4.74%-4.57%-15.32%-2.80%PHATPhathom Pharmaceuticals+1.11%+2.25%+14.37%+41.33%-16.66%TLXTelix Pharmaceuticals+0.93%+0.18%-0.46%-23.38%+1,087,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.81+0.4%$23.31$13.40▼$26.65$3.67B0.752.17 million shs412,372 shsADMAADMA Biologics$16.02+5.1%$15.85$13.50▼$25.67$3.80B0.473.16 million shs1.47 million shsPHATPhathom Pharmaceuticals$13.28-2.4%$11.97$2.21▼$19.50$945.28M0.431.64 million shs180,518 shsTLXTelix Pharmaceuticals$10.79-0.8%$10.29$8.93▼$30.36$3.66BN/A79,832 shs26,136 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+1.59%+5.38%-7.92%-6.54%+52.06%ADMAADMA Biologics+0.59%+4.74%-4.57%-15.32%-2.80%PHATPhathom Pharmaceuticals+1.11%+2.25%+14.37%+41.33%-16.66%TLXTelix Pharmaceuticals+0.93%+0.18%-0.46%-23.38%+1,087,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3334.51% UpsideADMAADMA Biologics 3.25Buy$27.6772.66% UpsidePHATPhathom Pharmaceuticals 2.71Moderate Buy$17.5031.78% UpsideTLXTelix Pharmaceuticals 2.75Moderate Buy$21.0094.62% UpsideCurrent Analyst Ratings BreakdownLatest PHAT, TLX, ACAD, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)10/24/2025TLXTelix PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TLXTelix PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/6/2025TLXTelix PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/29/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$34.00 ➝ $33.009/27/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Buy (B-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.84$0.72 per share30.35$4.40 per share4.96ADMAADMA Biologics$426.45M8.97$0.57 per share28.01$1.48 per share10.83PHATPhathom Pharmaceuticals$55.25M17.05N/AN/A($3.71) per share-3.58TLXTelix Pharmaceuticals$516.72M7.07$0.11 per share94.40$1.12 per share9.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.3428.697.3921.80%14.69%9.41%11/5/2025 (Estimated)ADMAADMA Biologics$197.67M$0.8618.5123.22N/A44.06%41.01%28.47%11/6/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%10/30/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0022.48N/AN/AN/AN/AN/ALatest PHAT, TLX, ACAD, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A10/30/2025Q3 2025PHATPhathom Pharmaceuticals-$0.30N/AN/AN/A$47.03 millionN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83ADMAADMA Biologics0.215.332.78PHATPhathom PharmaceuticalsN/A2.382.35TLXTelix PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ADMAADMA Biologics75.68%PHATPhathom Pharmaceuticals99.01%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ADMAADMA Biologics3.50%PHATPhathom Pharmaceuticals23.00%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableADMAADMA Biologics530238.63 million230.28 millionOptionablePHATPhathom Pharmaceuticals11070.94 million54.63 millionOptionableTLXTelix PharmaceuticalsN/A338.46 millionN/AN/APHAT, TLX, ACAD, and ADMA HeadlinesRecent News About These CompaniesTelix Pharmaceuticals Limited Investigated by the Portnoy Law FirmOctober 23 at 2:08 PM | globenewswire.comTLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal ImagingOctober 23 at 12:36 PM | tirto.idTWhy Telix shares could rise almost 40%October 22 at 6:46 PM | msn.comTelix Doses First Patient in SOLACE Trial for Metastatic Bone PainOctober 22 at 4:00 PM | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 22 at 12:54 PM | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?October 22 at 12:44 PM | marketbeat.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXOctober 20, 2025 | prnewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 19, 2025 | globenewswire.comWilliam Blair Has Positive Outlook of TLX FY2025 EarningsOctober 18, 2025 | americanbankingnews.comWedbush Reduces Earnings Estimates for Telix PharmaceuticalsOctober 17, 2025 | americanbankingnews.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 16, 2025 | globenewswire.comWedbush Has Bearish Forecast for TLX FY2025 EarningsOctober 16, 2025 | marketbeat.comResearch Analysts Set Expectations for TLX FY2025 EarningsOctober 16, 2025 | marketbeat.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXOctober 15, 2025 | prnewswire.comTELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of StockholdersOctober 15, 2025 | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Here's What HappenedOctober 15, 2025 | marketbeat.comWedbush Equities Analysts Lower Earnings Estimates for TLXOctober 15, 2025 | marketbeat.comTelix Pharmaceuticals shares jump as Q3 revenue rises 53% and guidance is upgradedOctober 14, 2025 | msn.comTelix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales GuidanceOctober 14, 2025 | benzinga.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What HappenedOctober 14, 2025 | marketbeat.comTelix Reports US$206M Revenue, FY 2025 Guidance UpgradedOctober 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHAT, TLX, ACAD, and ADMA Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.81 +0.08 (+0.36%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.ADMA Biologics NASDAQ:ADMA$16.02 +0.77 (+5.08%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Phathom Pharmaceuticals NASDAQ:PHAT$13.28 -0.33 (-2.42%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Telix Pharmaceuticals NASDAQ:TLX$10.79 -0.09 (-0.83%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
